Beneficial effect of adjuvant dabrafenib plus trametinib on recurrence-free survival in patients with resected BRAFV600-mutant stage III melanoma seems to be short-lived

Kenneth R. Hess

Research output: Contribution to journalLetterpeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)1354-1355
Number of pages2
JournalJournal of Clinical Oncology
Volume37
Issue number15
DOIs
StatePublished - May 20 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

MD Anderson CCSG core facilities

  • Biostatistics Resource Group

Cite this